ArticleDiabetes care2021
Incidence of Proliferative Diabetic Retinopathy and Other Neovascular Sequelae at 5 Years Following Diagnosis of Type 2 Diabetes.
Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Diabetic retinopathy treatment cascade and care continuum in the USA: a systematic review.BMJ open · 2026Pooled it
- L-Threonic Acid Inhibits Pathological Retinal Neovascularization by Modulation of CCL3-CCR5 Signaling Pathway.Investigative ophthalmology & visual science · 2026Article
- Human single-cell atlas of proliferative diabetic retinopathy reveals a SOX15-overexpressing stromal population driving retinal fibrosis through the endothelin-1 -EDNRB axis.Journal of translational medicine · 2026Article
- Efficient Synthesis of Glucovanillin and Elucidation of Its Molecular Mechanisms in Ameliorating T2DM via Core Target Modulation and α-Glucosidase Inhibition.Molecules (Basel, Switzerland) · 2026Article
- Article
- Semaglutide and diabetic retinopathy: an OHDSI network study.BMJ open diabetes research & care · 2025 · on this mapObservational
- Diabetic Retinopathy Screening Among Federally Qualified Health Center Patients Using Point-of-Care AI: DRES-POCAI: A Trial Protocol.JAMA network open · 2025Article
- Association of diabetic ketoacidosis and retinopathy in patients with type 2 diabetes: a nationwide cohort study.Scientific reports · 2025Article
- Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.Diabetologia · 2025Article
- The Long-Standing Problem of Proliferative Retinopathies: Current Understanding and Critical Cues.Cells · 2025Review
- Diabetic retinopathy: a comprehensive review of pathophysiology and emerging treatments.Molecular biology reports · 2025Review
- A risk prediction model for neovascular glaucoma secondary to proliferative diabetic retinopathy based on Boruta feature selection and random forest.Frontiers in cell and developmental biology · 2025Article
- Is longer axial length protective of vision-threatening diabetic retinopathy across different ages? A multicenter cohort of 736 patients.International journal of retina and vitreous · 2024Article
- The Association of Smoking Status with Diabetic Microvascular Complications in Korean Patients with Type 2 Diabetes.Yonsei medical journal · 2024Article
- MiR-9-3 hypermethylation is associated with stages of diabetic retinopathy.Journal of diabetes and metabolic disorders · 2024Article
- Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.BMC ophthalmology · 2024Article
- Present and future screening programs for diabetic retinopathy: a narrative review.International journal of retina and vitreous · 2024Review
- Healthcare Resource Utilization and Costs in an At-Risk Population With Diabetic Retinopathy.Translational vision science & technology · 2024Article
- Novel lipid mediator 7Frontiers in cell and developmental biology · 2024Article
- Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine the incidence and risk factors for developing proliferative diabetic retinopathy (PDR), tractional retinal detachment (TRD), and neovascular glaucoma (NVG) at 5 years after the initial diagnosis of type 2 diabetes. RESEARCH DESIGN AND
methodsInsured patients aged ≥18 years with newly diagnosed type 2 diabetes and 5 years of continuous enrollment were identified from a nationwide commercial claims database containing data from 2007 to 2015. The incidences of PDR, TRD, and NVG were computed at 5 years following the index diagnosis of type 2 diabetes. Associations between these outcomes and demographic, socioeconomic, and medical factors were tested with multivariable logistic regression.
resultsAt 5 years following the initial diagnosis of type 2 diabetes, 1.74% (1,249 of 71,817) of patients had developed PDR, 0.25% of patients had developed TRD, and 0.14% of patients had developed NVG. Insulin use (odds ratio [OR] 3.59, 95% CI 3.16-4.08), maximum HbA
conclusionsA subset of patients with type 2 diabetes develop PDR and other neovascular sequelae within the first 5 years following the diagnosis with type 2 diabetes. These patients may benefit from increased efforts for screening and early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.